The abstract is read at the publisher; the summary is JClub's.
A PK/PD–PBPK model in pregnant rats defines a dexamethasone therapeutic window of 1.63–17 ng/ml that balances foetal lung maturation against offspring neurotoxicity.
- Why it matters: Dexamethasone is used to treat NRDS by maturing foetal lungs, but its prenatal exposure is linked to offspring neurotoxicity, leaving uncertainty about an effective yet safe dose range.
- What they did: Pregnant rats received 0.1 or 0.4 mg·kg−1 dexamethasone, foetal surfactant proteins A and B were quantified, and a PK/PD model estimated a minimum effective concentration of 1.63 ng/ml; offspring behaviour was tested and hippocampal mRNA sequencing plus H19-7/IGF-IR concentration-toxicity assays supported a neurotoxic threshold of 17 ng/ml.
- The result: Using maternal–foetal PBPK simulations and a clinical pregnant-women PBPK, a reduced regimen of 2.5 or 3 mg every 8 h for six doses is predicted to fit the 1.63–17 ng/ml window.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.